Achiko AG: Invitation to the H1 2021 Financial Results Presentation

Achiko AG: Invitation to the H1 2021 Financial Results Presentation

EQS Group


EQS Group-News: Achiko AG / Key word(s): Conference
23.09.2021 / 13:30*Achiko AG: Invitation to the H1 2021 Financial Results Presentation*

*Zurich, 23 September 2021*

Achiko AG (SWX: ACHI, ISIN CH0522213468), a global healthtech company currently developing technologies that seek to deliver rapid, affordable diagnostic testing for Covid-19 and a range of other pathogenic diseases and therapeutic indications, will hold a H1 2021 Financial Results Presentation.

The event will be conducted as a virtual Zoom Meeting, led by Steven Goh, CEO of Achiko AG, and Robert Rieder, CFO of Achiko AG. Please note that the presentation will be in English.

*Date: Monday, September 27, 2021 at 08.00 a.m. (CEST)*
*Location: The presentation will be broadcast live as a virtual Zoom meeting via this link (**). *

Participants are advised to log on to the conference and register their details 10 minutes prior to the conference call.

The company's H1 2021 financial results will be released on Monday, September 27, 2021 at 06:30 a.m. (CEST) and will be made available on our website at

A replay of the presentation and the Q&A session will be available shortly after the conference call and can be accessed any time on our website at

Kind regards,
Achiko Investor Relations*ABOUT ACHIKO AG*
Achiko creates and develops new innovations in healthcare technology through its biotechnology division, AptameX^TM, and its sister digital mobile health technology division, Teman Sehat^TM. The Company has created a unique healthtech capability that provides user-friendly diagnostic testing integrated with a digital passport solution for the management of Covid-19.

AptameX comprises of DNA aptamer-based technology that is cost-effective, chemically synthesised and widely applicable to the evolving diagnostic field of healthcare. Together with the digital mobile health app Teman Sehat, Achiko is developing potential technologies that seek to deliver rapid, affordable diagnostic testing for a range of pathogenic diseases and therapeutic indications. The AptameX technology is licensed from and Achiko has exclusive commercialisation rights.

Headquartered in Zurich, Achiko has offices in Hong Kong, Jakarta, Seoul and Singapore.

Further information can be found at

*Media contacts: *

Investor Relations

*Switzerland & Global*
Marcus Balogh
Farner Consulting Ltd.
T: +41 44 266 67 67

*U.S. & Global*
Jeanene Timberlake
T: +1 646 770 8858

This communication expressly or implicitly contains certain forward-looking statements concerning Achiko AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Achiko AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Achiko AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

End of Media Release --------------------

Language: English
Company: Achiko AG
Tessinerplatz 7
8002 Zurich
ISIN: CH0522213468
Valor: 48788430
Listed: SIX Swiss Exchange
EQS News ID: 1235590
End of News EQS Group News Service

Full Article